Company intelligence / Profile preview
Regeneron Pharmaceuticals
Tarrytown, New York, United Statesregeneron.com ↗
- Ownership
- Public · REGN
- Employees
- ~15100
- Development stage
- Commercial
01
Overview
Regeneron has several approved drugs including aflibercept (EYLEA) for eye diseases, rilonacept (ARCALYST) for rare autoinflammatory diseases, dupilumab (Dupixent) for allergic conditions, and cemiplimab (Libtayo) for cancer. The company has demonstrated strong efficacy and reached blockbuster status for EYLEA and Dupixent while rapidly advancing innovative candidates from genetics and antibody platforms. EYLEA HD (high dose) was approved in 2023; rapid COVID-19 therapeutics such as REGEN-COV have also been deployed in response to global needs.
- Therapeutic areas
- ImmunologyOphthalmologyInfectious DiseasesHematologyCardiovascularOncologyNeurology
- Modalities
- Monoclonal antibodyBispecific monoclonal antibodyTrap fusion proteinGene therapyBiologicSmall molecule
- Industry
- Pharma
02
Drug pipeline
136 assets135 more assets in the full pipeline.
03
Partnerships
04
Financials
- Market cap
- $93.4B
- Total revenue
- $14.3B
- Enterprise value
- $86.8B
Beyond the preview
Go deeper on Regeneron Pharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Regeneron Pharmaceuticals.